Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis

An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of SBI-087 Administered To Subjects With Rheumatoid Arthritis

The purpose of this study is to determine the safety and tolerability of single doses of SBI-087 in subjects with rheumatoid arthritis.

Inclusion Criteria:

• Man or nonlactating and nonpregnant woman, aged 18 to 70 years, inclusive, at the screening visit.
• Must meet criteria for rheumatoid arthritis with functional class I to III.
• Diagnosis of rheumatoid arthritis more than 6 months before study day 1 and rheumatoid arthritis onset after 16 years of age

Exclusion Criteria:

• Any significant health problems other than rheumatoid arthritis.
• Treatment of greater than 10 mg of prednisone per day.
• Treatment with cyclophosphamide.